Gilead Sciences' Kite unit has showcased three new CAR-T therapies at ASH, headed by multiple myeloma candidate ...

The company's BCMAxCD3 bispecific antibody Lynozyfic (linvoseltamab) got its first FDA approval as a fifth-line or later ...

This approach offers an enhanced therapeutic effect with minimal systemic toxicity, addressing one of oncology’s ...

Social determinants of health (SDOH) encompass a wide range of non-medical factors that influence health and well-being.

In line with its deregulatory stance under new Commissioner Marty Makary, the US regulator has launched TEMPO – ...

And Simon Kohl, founder and CEO of Latent Labs, knows this intimately. In a new episode of the pharmaphorum podcast, Kohl ...

At this year's ASH congress, the results of the phase 1b/2 DURGA-1 of AZD0120 – a dual BCMA and CD19-directed CAR-T therapy – ...

The FDA has now started a review of the highly anticipated drug, and AZ is using a priority review voucher to shorten the ...

Bayer has started a phase 2a trial of an antibody that it hopes could provide a targeted, potentially disease-modifying ...

CD19-targeted therapy Breyanzi (lisocabtagene maraleucel) can now be used to treat adults with MZL – a rare and form of ...

Eli Lilly's fast-growing blood cancer drug Jaypirca has bagged a new FDA approval as an earlier treatment for relapsed or ...

The verdict is the latest twist in patent litigation between MSD and Halozyme, in which the latter is claiming that Keytruda ...